Curaleaf Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Curaleaf Holdings şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding

Nov 09

Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

Aug 13

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Jul 19

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Jun 14

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Jan 19

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CURA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CURA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Curaleaf Holdings Piyasaya Karşı Temettü Getirisi

CURA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CURA)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.1%
Sektör Ortalaması (Pharmaceuticals)	2.5%
Analist tahmini (CURA) (3 yıla kadar)	n/a

Önemli Temettü: CURA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CURA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CURA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CURA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Curaleaf Holdings Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Share price stability

Investors Give Curaleaf Holdings, Inc. (TSE:CURA) Shares A 27% Hiding

Consensus EPS estimates fall by 10%

Curaleaf Holdings, Inc. (TSX:CURA) acquired Half Moon Nursery, Inc. and The assets of Dark Heart Nursery from Grace & Co., Inc. for approximately $2 million.

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Curaleaf Holdings, Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Profitability

Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

New minor risk - Profitability

Second quarter 2024 earnings: EPS misses analyst expectations

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Curaleaf Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Executive Vice-Chairman recently sold CA$706k worth of stock

Consensus EPS estimates fall by 17%

Curaleaf Holdings, Inc. (TSX:CURA) completed the acquisition of Northern Green Canada Inc. (NGC).

Curaleaf Holdings, Inc., Annual General Meeting, Jun 14, 2024

Curaleaf Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

Curaleaf Holdings, Inc. (TSX:CURA) signed a deal to acquire Northern Green Canada Inc. (NGC).

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Curaleaf Expands Zero Proof™ Brand Portfolio with Launch of Stir Fast-Acting THC Beverage Mix

Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 36%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Curaleaf Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Executive Vice-Chairman recently sold CA$860k worth of stock

Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Curaleaf Expands Brand Portfolio with Launch of Zero Proof ™ Cannabis-Infused Drinkables

Curaleaf Holdings, Inc., Annual General Meeting, Oct 04, 2023

Curaleaf Holdings, Inc.'s Select™ Brand Expands Product Offerings With Launch of Select Liquid Diamonds

Second quarter 2023 earnings: EPS misses analyst expectations

Curaleaf Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Curaleaf Holdings, Inc. Unveils Strategic National Rebrand of Select

New minor risk - Shareholder dilution

Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

Consensus EPS estimates fall by 66%

Forecast breakeven date moved forward to 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Closure of Operations in California, Colorado and Oregon

Forecast to breakeven in 2025

Less than half of directors are independent

Curaleaf Holdings, Inc. Announces Expansion of BlueKudu Infused Chocolate Flavors Available on Florida Retail Menus

Curaleaf Holdings, Inc. Announces the Launch of Adult-Use Sales At Its Bordentown, New Jersey Location

Curaleaf Holdings Relocates Deerfield, IL Dispensary and Opens Doors to Adult-Use Customers

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) completed the acquisition of Tryke Companies, LLC for approximately $180 million.

Executive Vice-Chairman recently sold CA$160k worth of stock

We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

No longer forecast to breakeven

Consensus EPS estimates fall by 42%

No longer forecast to breakeven

Curaleaf Holdings, Inc., Annual General Meeting, Sep 08, 2022

Curaleaf Holdings, Inc. Announces Management Appointments

Curaleaf Holdings, Inc. Launches Plant Precision, New Product Line Targeting Specific Health and Wellness Categories

Consensus forecasts updated

Curaleaf Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Curaleaf Expands New Jersey Adult-Use Sales to Edgewater Park Dispensary

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

First quarter 2022 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. Reports Impairment Loss for the Quarter Ended March 21, 2022

Curaleaf Holdings, Inc. Announces Executive Changes

Consensus forecasts updated

Forecast breakeven date pushed back to 2023

Curaleaf Holdings, Inc Expands Product Offerings With Launch of BlueKudu Chocolates in Florida

Curaleaf Holdings, Inc., Annual General Meeting, Jun 23, 2022

Curaleaf Holdings, Inc. Announces its Select Brand Launches Limited-Edition Cliq Elite Live Strain in California

Curaleaf Holdings, Inc. to Report Q1, 2022 Results on May 09, 2022

Interim Chief Financial Officer exercised options to buy CA$851k worth of stock.

Curaleaf Holdings, Inc. Reports Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Curaleaf Holdings, Inc. (CNSX:CURA) completed the acquisition of Bloom Dispensaries.

Curaleaf Holdings, Inc. (CNSX:CURA) entered into a definitive agreement to acquire Bloom Dispensaries for approximately $210 million.

Curaleaf Holdings, Inc. (CNSX:CURA) agreed to acquire Natural Remedy Patient Center, LLC for $13 million.